Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 9/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 4/20 | 0.50 |
| ▸ | AKT2 | P31751 | 1/20 | 0.50 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.50 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509578 | 0.94 | AKT1 (0.62) | AKT1ENPP2LMNAMAPTMC4R | |
| Hydrochloric Acid SCHEMBL4529692 | 0.93 | AKT1 (0.61) | AKT1ENPP2LMNAMAPTMC4R | |
| Hydrochloric Acid SCHEMBL5334071 | 0.93 | AKT1 (0.61) | AKT1ENPP2LMNAMAPTMC4R | |
| SCHEMBL4517707 | 0.78 | MC4R (0.55) | ENPP2LMNAMAPTMC4R | |
| SCHEMBL14355905 | 0.75 | AKT1 (0.59) | AKT1MC4RAKT2AKT1S1AKT3 | |
| SCHEMBL14355910 | 0.75 | AKT1 (0.61) | AKT1MC4RAKT2AKT1S1AKT3 | |
| Hydrochloric Acid SCHEMBL5338187 | 0.74 | AKT1 (0.60) | AKT1MC4RAKT2AKT1S1AKT3 | |
| SCHEMBL14355904 | 0.74 | AKT1 (0.60) | AKT1MC4RAKT2AKT1S1AKT3 | |
| SCHEMBL4515320 | 0.73 | MC4R (0.63) | AKT1MC4RAKT2AKT1S1AKT3 | |
| SCHEMBL6613167 | 0.73 | AKT1 (0.59) | AKT1MC4RAKT2AKT1S1AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | AKT1 2882/4885ENPP2 475/4885LMNA 3009/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | AKT1 2882/4885ENPP2 475/4885LMNA 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.